![[höher]](/style/images/multi_up.png)
Eine Ebene höherGruppiert nach: Dokumententyp |
Veröffentlichungsdatum
Anzahl der Publikationen: 70
2023
Weiss, L.; Dorman, K.; Boukovala, M.; Schwinghammer, F.; Jordan, P.; Fey, T.; Hasselmann, K.; Subklewe, Marion; Bücklein, V.; Bargou, R.; Goebeler, M.; Sayehli, C.; Spoerl, S.; Lüke, F.; Heudobler, D.; Claus, R.; Luettichau, I. von; Lorenzen, S.; Lange, S.; Westphalen, C. B.; Bergwelt-Baildon, Michael von 
ORCID: https://orcid.org/0000-0002-1952-052X; Heinemann, V. und Gießen-Jung, Clemens ORCID: https://orcid.org/0000-0003-0537-1727
(2023):
Early clinical trial unit tumor board: a real-world experience in a national cancer network.
In: Journal of Cancer Research and Clinical Oncology, Bd. 149, Nr. 14: S. 13383-13390
[PDF, 889kB]
ORCID: https://orcid.org/0000-0002-1952-052X; Heinemann, V. und Gießen-Jung, Clemens ORCID: https://orcid.org/0000-0003-0537-1727
(2023):
Early clinical trial unit tumor board: a real-world experience in a national cancer network.
In: Journal of Cancer Research and Clinical Oncology, Bd. 149, Nr. 14: S. 13383-13390
[PDF, 889kB]
2022
Kruger, S. F.; Lohneis, A.; Abendroth, A.; Berger, A. W.; Ettrich, T. J.; Waidmann, O.; Kapp, M.; Steiner, B.; Kumbrink, J.; Reischer, A.; Haas, M.; Westphalen, C. B.; Zhang, D.; Miller-Phillips, L.; Burger, P. J.; Kobold, S.; Werner, J.; Subklewe, M.; Bergwelt-Baildon, M. von; Kunzmann, V.; Seufferlein, T.; Siveke, J. T.; Sinn, M.; Heinemann, V.; Ormanns, S. und Boeck, S.
(2022):
Prognosis and tumor biology of pancreatic cancer patients with isolated lung metastases: translational results from the German multicenter AIO-YMO-PAK-0515 study.
In: ESMO Open, Bd. 7, Nr. 1, 100388
Sommerhäuser, G.; Kurreck, A.; Stintzing, S.; Heinemann, V.; Fischer von Weikersthal, L.; Dechow, T.; Kaiser, F.; Karthaus, M.; Schwaner, I.; Fuchs, M.; König, A.; Roderburg, C.; Hoyer, I.; Quante, M.; Kiani, A.; Fruehauf, S.; Müller, L.; Reinacher-Schick, A.; Ettrich, T. J.; Stahler, A. und Modest, D. P.
(2022):
Study protocol of the FIRE-8 (AIO-KRK/YMO-0519) trial: a prospective, randomized, open-label, multicenter phase II trial investigating the efficacy of trifluridine/tipiracil plus panitumumab versus trifluridine/tipiracil plus bevacizumab as first-line treatment in patients with metastatic colorectal cancer.
In: BMC Cancer, Bd. 22, Nr. 1, 820
Hartlapp, I.; Valta-Seufzer, D.; Siveke, J. T.; Algul, H.; Goekkurt, E.; Siegler, G.; Martens, U. M.; Waldschmidt, D.; Pelzer, U.; Fuchs, M.; Kullmann, F.; Boeck, S.; Ettrich, T. J.; Held, S.; Keller, R.; Anger, F.; Germer, C. T.; Stang, A.; Kimmel, B.; Heinemann, V. und Kunzmann, V.
(2022):
Prognostic and predictive value of CA 19-9 in locally advanced pancreatic cancer treated with multiagent induction chemotherapy: results from a prospective, multicenter phase II trial (NEOLAP-AIO-PAK-0113).
In: ESMO Open, Bd. 7, Nr. 4
Pretzsch, E.; Niess, H.; Boesch, F.; Westphalen, C. B.; Jacob, S.; Neumann, J.; Werner, J.; Heinemann, V. und Angele, M. K.
(2022):
Age and metastasis - How age influences metastatic spread in cancer. Colorectal cancer as a model.
In: Cancer Epidemiology, Bd. 77, 102112
2021
Sams, L.; Kruger, S.; Heinemann, V.; Bararia, D.; Häbe, S.; Alig, S.; Haas, M.; Zhang, D.; Westphalen, C. B.; Ormanns, S.; Metzger, P.; Werner, J.; Weigert, O.; von Bergwelt-Baildon, M.; Rataj, F.; Kobold, S. und Böck, S.
(2021):
Alterations in regulatory T cells and immune checkpoint molecules in pancreatic cancer patients receiving FOLFIRINOX or gemcitabine plus nab-paclitaxel.
In: Clinical & Translational Oncology, Bd. 23, Nr. 11: S. 2394-2401
Heilig, C. E.; Horak, P.; Kreutzfeldt, S.; Teleanu, V.; Mock, A.; Renner, M.; Bhatti, I. A.; Hutter, B.; Huellein, J.; Froehlich, M.; Uhrig, S.; Suesse, H.; Heiligenthal, L.; Ochsenreither, S.; Illert, A. L.; Vogel, A.; Desuki, A.; Heinemann, V.; Heidegger, S.; Bitzer, M.; Scheytt, M.; Brors, B.; Huebschmann, D.; Baretton, G.; Stenzinger, A.; Steindorf, K.; Benner, A.; Jaeger, D.; Heining, C.; Glimm, H.; Froehling, S. und Schlenk, R. F.
(2021):
Rationale and design of the CRAFT (Continuous ReAssessment with Flexible ExTension in Rare Malignancies) multicenter phase II trial.
In: Esmo Open, Bd. 6, Nr. 6
Haas, M.; Waldschmidt, D. T.; Stahl, M.; Reinacher-Schick, A.; Freiberg-Richter, J.; Fischer von Weikersthal, L.; Kaiser, F.; Kanzler, S.; Frickhofen, N.; Seufferlein, T.; Dechow, T.; Mahlberg, R.; Malfertheiner, P.; Illerhaus, G.; Kubicka, S.; Abdul-Ahad, A.; Snijder, R.; Kruger, S.; Westphalen, C. B.; Held, S.; Bergwelt-Baildon, M. von; Boeck, S. und Heinemann, V.
(2021):
Afatinib plus gemcitabine versus gemcitabine alone as first-line treatment of metastatic pancreatic cancer: The randomised, open-label phase II ACCEPT study of the Arbeitsgemeinschaft Internistische Onkologie with an integrated analysis of the 'burden of therapy' method.
In: European Journal of Cancer, Bd. 146: S. 95-106
Erickson, Nicole; Schinkoethe, T.; Eckhardt, C.; Storck, L.; Joos, A.; Liu, L.; Ballmer, P. E.; Mumm, F.; Fey, T. und Heinemann, V.
(2021):
Patient-reported outcome measures obtained via E-Health tools ease the assessment burden and encourage patient participation in cancer care (PaCC Study).
In: Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, Bd. 29, Nr. 12: S. 7715-7724
[PDF, 768kB]
Sams, L.; Kruger, S.; Heinemann, V.; Bararia, D.; Haebe, S.; Alig, S.; Haas, M.; Zhang, D.; Westphalen, C. B.; Ormanns, S.; Metzger, P.; Werner, J.; Weigert, O.; von Bergwelt-Baildon, M.; Rataj, F.; Kobold, S. und Boeck, S.
(2021):
Alterations in regulatory T cells and immune checkpoint molecules in pancreatic cancer patients receiving FOLFIRINOX or gemcitabine plus nab-paclitaxel.
In: Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico
[PDF, 1MB]
2020
Kurreck, A.; Geissler, M.; Martens, U. M.; Riera-Knorrenschild, J.; Greeve, J.; Florschütz, A.; Wessendorf, S.; Ettrich, T.; Kanzler, S.; Nörenberg, D.; Seidensticker, M.; Held, S.; Buechner-Steudel, P.; Atzpodien, J.; Heinemann, V.; Stintzing, S.; Seufferlein, T.; Tannapfel, A.; Reinacher-Schick, A. C. und Modest, D. P.
(2020):
Dynamics in treatment response and disease progression of metastatic colorectal cancer (mCRC) patients with focus on BRAF status and primary tumor location: analysis of untreated RAS-wild-type mCRC patients receiving FOLFOXIRI either with or without panitumumab in the VOLFI trial (AIO KRK0109).
In: Journal of Cancer Research and Clinical Oncology, Bd. 146, Nr. 10: S. 2681-2691
2018
Haas, M.; Siveke, J. T.; Schenk, M.; Lerch, M. M.; Caca, K.; Freiberg-Richter, J.; Fischer von Weikersthal, L.; Kullmann, F.; Reinacher-Schick, A.; Fuchs, M.; Kanzler, S.; Kunzmann, V.; Ettrich, T. J.; Kruger, S.; Westphalen, C. B.; Held, S.; Heinemann, V. und Böck, S.
(2018):
Efficacy of gemcitabine plus erlotinib in rash-positive patients with metastatic pancreatic cancer selected according to eligibility for FOLFIRINOX: A prospective phase II study of the 'Arbeitsgemeinschaft Internistische Onkologie'.
In: European Journal of Cancer, Bd. 94: S. 95-103
Holch, J. W.; Ricard, I.; Stintzing, Sebastian; Fischer von Weikersthal, Ludwig; Decker, T.; Kiani, A.; Vehling-Kaiser, U.; Heintges, T.; Kahl, C.; Kullmann, F.; Scheithauer, W.; Moehler, M.; Jelas, I.; Modest, D. P.; Westphalen, C. B.; Einem, J. C. von; Michl, M. und Heinemann, V.
(2018):
Relevance of baseline carcinoembryonic antigen for first-line treatment against metastatic colorectal cancer with FOLFIRI plus cetuximab or bevacizumab (FIRE-3 trial).
In: European Journal of Cancer, Bd. 106: S. 115-125
Krüger, S.; Heinemann, V.; Ross, C.; Diehl, F.; Nagel, D.; Ormanns, S.; Liebmann, S.; Prinz-Bravin, I.; Westphalen, C. B.; Haas, M.; Jung, A.; Kirchner, T.; Bergwelt-Baildon, M. von; Böck, S. und Holdenrieder, S.
(2018):
Repeated (mut)KRAS ctDNA measurements represent a novel and promising tool for early response prediction and therapy monitoring in advanced pancreatic cancer.
In: Annals of Oncology, Bd. 29, Nr. 12: S. 2348-2355
Sebio, A.; Stintzing, S.; Heinemann, V.; Sunakawa, Y.; Zhang, W.; Ichikawa, W.; Tsuji, A.; Takahashi, T.; Parek, A.; Yang, D.; Cao, S.; Ning, Y.; Stremitzer, S.; Matsusaka, S.; Okazaki, S.; Barzi, A.; Berger, M. D. und Lenz, H-J
(2018):
A genetic variant in Rassf1a predicts outcome in mCRC patients treated with cetuximab plus chemotherapy: results from FIRE-3 and JACCRO 05 and 06 trials.
In: Pharmacogenomics Journal, Bd. 18, Nr. 1: S. 43-48
2017
Geissler, M.; Martens, U. M.; Knorrenschield, R.; Greeve, J.; Florschütz, A.; Tannapfel, A.; Wessendorf, S.; Seufferlein, T.; Kanzler, S.; Heinemann, V.; Held, S. und Reinacher-Schick, A.
(2017):
mFOLFOXIRI plus panitumumab versus FOLFOXIRI as first-line treatment in patients with RAS wild-type metastatic colorectal cancer m(CRC): A randomized phase II VOLFI trial of the AIO (AIO-KRK0109).
In: Annals of Oncology, Bd. 28
Stintzing, S.; Miller-Phillips, L.; Modest, D. P.; Fischer von Weikersthal, L.; Decker, T.; Kiani, A.; Vehling-Kaiser, U.; Al-Batran, S-E.; Heintges, T.; Kahl, C.; Seipelt, G.; Kullmann, F.; Stauch, M.; Scheithauer, W.; Held, S.; Moehler, M.; Jagenburg, A.; Kirchner, T.; Jung, A. und Heinemann, V.
(2017):
Impact of BRAF and RAS mutations on first-line efficacy of FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab: analysis of the FIRE-3 (AIO KRK-0306) study.
In: European Journal of Cancer, Bd. 79: S. 50-60
Modest, D. P.; Fischer von Weikersthal, L.; Decker, T.; Vehling-Kaiser, U.; Uhlig, J.; Schenk, M.; Freiberg-Richter, J.; Peuser, B.; Denzlinger, C.; Reddemann, C. Peveling Genannt; Graeven, U.; Schuch, G.; Schwaner, I.; Stahler, A.; Jung, A.; Held, S.; Stintzing, S.; Giessen-Jung, C. und Heinemann, V.
(2017):
Sequential first-line therapy of metastatic colorectal cancer (mCRC) starting with fluoropyrimidine (FP) plus bevacizumab (BEV) vs. initial FP plus irinotecan (IRI) and BEV: German AIO KRK0110 (ML22011) study.
In: Annals of Oncology, Bd. 28
Stintzing, S.; Price, B.; Knight, L.; McCavigan, A.; Walker, S.; Harkin, P.; Kennedy, R.; Neureiter, D.; Held, S.; Jung, A.; Kirchner, T. und Heinemann, V.
(2017):
Predictive assay for anti-angiogenic agents (AADx) identifies molecular subgroups of RASwt mCRC with differential efficacy of FOLFIRI plus bevacizumab in the FIRE-3 (AIO KRK-0306) trial.
In: Annals of Oncology, Bd. 28
Böck, S.; Mehraein, Y.; Ormanns, S.; Kruger, S.; Westphalen, C. Benedikt; Haas, M.; Jung, A.; Kirchner, T. und Heinemann, V.
(2017):
Mismatch-repair-deficient metastatic pancreatic ductal adenocarcinoma with a germline PALB2 mutation: unusual genetics, unusual clinical course.
In: Annals of Oncology, Bd. 28, Nr. 2: S. 438-439
Modest, D. P.; Denecke, T.; Pratschke, J.; Lang, H.; Bemelmans, M.; Becker, T.; Rentsch, M.; Seehofer, D.; Bruns, C. J.; Gebauer, B.; Stintzing, S.; Modest, H. I.; Held, S.; Folprecht, G.; Heinemann, V. und Neumann, U. P.
(2017):
Central evaluation for surgical treatment options in FIRE-3-updated results and impact on overall survival.
In: Oncology Research and Treatment, Bd. 40: S. 122
Geissler, M.; Martens, U.; Knorrenschild, J. R.; Greeve, J.; Florschütz, A.; Tannapfel, A.; Mönnich, H.; Ettrich, T.; Kanzler, S.; Büchner-Steudel, P.; Heinemann, V.; Held, S.; Reinacher-Schick, A.; Hebart, H.; Atzpodien, J.; Egger, M.; Lindig, U. und Müller, C.
(2017):
mFOLFOXIRI plus Panitumumab versus FOLFOXIRI as first-line treatment in patients with RAS wild-type metastatic colorectal cancer m(CRC): a randomized phase II VOLFI trial of the AIO (AIO-KRK0109).
In: Oncology Research and Treatment, Bd. 40: S. 123
Holch, J. W.; Stintzing, S.; Held, S.; Fischer von Weikersthal, L.; Decker, T.; Kiani, A.; Vehling-Kaiser, U.; Al-Batran, S.-E.; Heintges, T.; Kahl, C.; Kullmann, F.; Scheithauer, W.; Kirchner, T.; Einem, J. C. von; Modest, D. P. und Heinemann, V.
(2017):
Right-sided colorectal cancer (RC): response to first-line chemotherapy in FIRE-3 (AIO KRK-0306) with focus on early tumor shrinkage (ETS) and depth of response (DpR).
In: Oncology Research and Treatment, Bd. 40: S. 164-165
Karthaus, M.; Kröning, H.; Bauer, S.; Brandt, K. und Heinemann, V.
(2017):
Safety and quality-of-life in patients treated with aflibercept and FOLFIRI as 2nd line treatment for their metastatic colorectal cancer (mCRC) - a German subgroup analysis of the Aflibercept Safety and Quality-of-Life Program (ASQoP).
In: Oncology Research and Treatment, Bd. 40: S. 167-168
Modest, D. P.; Fischer von Weikersthal, L.; Decker, T.; Vehling-Kaiser, U.; Uhlig, J.; Schenk, M.; Freiberg-Richter, J.; Peuser, B.; Denzlinger, C.; Reddemann, Peveling Genannt C.; Gräven, U.; Schuch, G.; Schwaner, I.; Stahler, A.; Jung, A.; Held, S.; Stintzing, S.; Giessen-Jung, C. und Heinemann, V.
(2017):
Randomized phase III study of fluoropyrimidine (FP) plus bevacizumab (BEV) vs. FP plus irinotecan (IRI) and BEV as first-line therapy for metastatic colorectal cancer (mCRC): german AIO KRK0110 (ML22011) - study.
In: Oncology Research and Treatment, Bd. 40: S. 123
Kruger, S.; Ormanns, S.; Rösgen, V.; Legenstein, M.-L.; Haas, M.; Westphalen, C. B.; Düwell, P.; Schnurr, M.; Heinemann, V.; Kirchner, T. und Böck, S.
(2017):
IDO1 expression as biomarker in erlotinib-treated patients with advanced pancreatic cancer: translational results from the AIO-PK0104 phase III trial.
In: Oncology Research and Treatment, Bd. 40: S. 235
Burger, P. J.; Kruger, S.; Jühling, A.; Kapp, M.; Berger, A. W.; Ormanns, S.; Ettrich, T. J.; Waidmann, O.; Steiner, B.; Kunzmann, V.; Abendroth, A.; Sinn, M.; Werner, J.; Kirchner, T.; Heinemann, V. und Böck, S.
(2017):
Isolated pulmonary metastases in pancreatic cancer: preliminary results from the retrospective multi-center AIO-YMO-PAK-0515 study.
In: Oncology Research and Treatment, Bd. 40: S. 236-237
Arnold, D.; Lueza, B.; Douillard, J.-Y.; Peeters, M.; Lenz, H.-J.; Venook, A.; Heinemann, V.; Cutsem, Eric van; Pignon, J.-P.; Tabernero, J.; Cervantes, A. und Ciardiello, F.
(2017):
Prognostic and predictive value of primary tumour side in patients with RAS wild-type metastatic colorectal cancer treated with chemotherapy and EGFR directed antibodies in six randomized trials.
In: Annals of Oncology, Bd. 28, Nr. 8: S. 1713-1729
Haas, M.; Böck, S.; Siveke, J. T.; Schenk, M.; Lerch, M.; Caca, K.; Freiberg-Richter, J.; Fischer von Weikersthal, L.; Kullmann, F.; Reinacher-Schick, A.; Fuchs, M.; Ettrich, T. J.; Kanzler, S.; Kunzmann, V.; Kruger, S.; Westphalen, C. B.; Held, S. und Heinemann, V.
(2017):
Efficacy of gemcitabine plus erlotinib for rash-positive metastatic pancreatic cancer patients eligible for treatment with FOLFIRINOX - a prospective phase II trial of the "Arbeitsgemeinschaft Internistische Onkologie" - AIO.
In: Oncology Research and Treatment, Bd. 40: S. 207-208
Bonnetain, F.; Borg, C.; Adams, R. R.; Ajani, J. A.; Benson, A.; Bleiberg, H.; Chibaudel, B.; Diaz-Rubio, E.; Douillard, J. Y.; Fuchs, C. S.; Giantonio, B. J.; Goldberg, R.; Heinemann, V.; Koopman, M.; Labianca, R.; Larsen, A. K.; Maughan, T.; Mitchell, E.; Peeters, M.; Punt, C. J. A.; Schmoll, H. J.; Tournigand, C. und Gramont, A. de
(2017):
How health-related quality of life assessment should be used in advanced colorectal cancer clinical trials.
In: Annals of Oncology, Bd. 28, Nr. 9: S. 2077-2085
Garcia-Corbacho, J.; Spira, A.; Boni, V.; Feliu, J.; Middleton, M.; Burris, H.; Weaver, A. Yang; Will, M.; Harding, J.; Meric-Bernstam, F. und Heinemann, V.
(2017):
PROCLAIM-CX-2009: A first-in-human trial to evaluate CX-2009 in adults with metastatic or locally advanced unresectable solid tumors.
In: Annals of Oncology, Bd. 28
Berger, M. D.; Stintzing, S.; Heinemann, V.; Yang, D.; Cao, S.; Sunakawa, Y.; Ning, Y.; Matsusaka, S.; Okazaki, S.; Miyamoto, Y.; Suenaga, M.; Schirripa, M.; Soni, S.; Zhang, W.; Falcone, A.; Loupakis, F. und Lenz, H.-J.
(2017):
Impact of genetic variations in the MAPK signaling pathway on outcome in metastatic colorectal cancer patients treated with first-line FOLFIRI and bevacizumab: data from FIRE-3 and TRIBE trials.
In: Annals of Oncology, Bd. 28, Nr. 11: S. 2780-2785
Wasan, H.; Sharma, R.; Heinemann, V.; Sharma, N.; Taieb, J.; Ricke, J.; Peeters, M.; Findlay, M.; Virdee, P. S.; Love, S.; Moschandreas, J.; Dutton, P.; Gebski, V.; Gray, A. M.; Price, D.; Bower, G.; Montazeri, A.; Gibbs, P. und Hazel, G. van
(2017):
FOXFIRE-SIRFLOX-FOXFIRE global prospective randomised studies of first-line selective internal radiotherapy (SIRT) in patients with liver metastases from colorectal cancer: KRAS mutation and tumour site analysis.
In: Annals of Oncology, Bd. 28
2016
Laurent-Puig, P.; Grisoni, M.-L.; Heinemann, V.; Fontaine, K.; Vazart, C.; Decaulne, V.; Rousseau, F.; Courtieu, B.; Lieabert, F.; Jung, A.; Neureiter, D.; Thiebaut, R. und Stintzing, S.
(2016):
MiR-31-3p is a predictive biomarker of cetuximab response in FIRE3 clinical trial.
In: Annals of Oncology, Bd. 27
Quante, A. S.; Ming, C.; Rottmann, Miriam; Engel, Jutta; Boeck, S.; Heinemann, V.; Westphalen, C. B. und Strauch, K.
(2016):
Projections of cancer incidence and cancer-related deaths in Germany by 2020 and 2030.
In: Cancer Medicine, Bd. 5, Nr. 9: S. 2649-2656
Stahler, A.; Stintzing, S.; Urbischek, M.; Modest, D. P.; Fischer von Weikersthal, L.; Kumbrink, J.; Heinemann, V.; Kirchner, T. und Jung, A.
(2016):
Targeting FGF2 expression against chemoresistance in colorectal cancer (CRC) cell lines - a potential prognostic biomarker in patients with metastatic colorectal cancer (mCRC) treated with FUFIRI or mIrOx (FIRE1).
In: Annals of Oncology, Bd. 27
Neumann, U.; Denecke, T.; Pratschke, J.; Lang, H.; Bemelmans, M.; Becker, T.; Rentsch, M.; Seehofer, D.; Bruns, C. J.; Gebauer, B.; Folprecht, G.; Stintzing, S.; Held, S.; Heinemann, V. und Modest, D. P.
(2016):
Evaluation for surgical treatment options in metastatic colorectal cancer (mCRC) - a retrospective, central evaluation of FIRE-3.
In: Annals of Oncology, Bd. 27
Stahler, A.; Heinemann, V.; Clemens, G.; Crispin, A.; Schalhorn, A.; Stintzing, S.; Fischer von Weikersthal, L.; Vehling-Kaiser, U.; Stauch, M.; Quietzsch, D.; Held, S.; Einem, J. C. von; Holch, J.; Neumann, J.; Kirchner, T.; Jung, A. und Modest, D. P.
(2016):
Prevalence and influence on outcome of Neuregulin- (NRG1), HER2/neu- and HER3-expression in patients with metastatic colorectal cancer (mCRC) treated with irinotecan-based first-line regimens (FUFIRI vs. mIROX) in the FIRE 1-trial.
In: Oncology Research and Treatment, Bd. 39: S. 72
Cutsem, E. van; Cervantes, A.; Adam, R.; Sobrero, A.; Krieken, J. H. van; Aderka, D.; Aranda Aguilar, E.; Bardelli, A.; Benson, A.; Bodoky, G.; Ciardiello, F.; D'Hoore, A.; Diaz-Rubio, E.; Douillard, J.-Y.; Ducreux, M.; Falcone, A.; Grothey, A.; Gruenberger, T.; Haustermans, K.; Heinemann, V.; Hoff, P.; Köhne, C.-H.; Labianca, R.; Laurent-Puig, P.; Ma, B.; Maughan, T.; Muro, K.; Normanno, N.; Österlund, P.; Oyen, W. J. G.; Papamichael, D.; Pentheroudakis, G.; Pfeiffer, P.; Price, T. J.; Punt, C.; Ricke, J.; Roth, A.; Salazar, R.; Scheithauer, W.; Schmoll, H. J.; Tabernero, J.; Taïeb, J.; Tejpar, S.; Wasan, H.; Yoshino, T.; Zaanan, A. und Arnold, D.
(2016):
ESMO consensus guidelines for the management of patients with metastatic colorectal cancer.
In: Annals of Oncology, Bd. 27, Nr. 8: S. 1386-1422
Modest, D. P.; Stintzing, S.; Fischer von Weikersthal, L.; Decker, T.; Kiani, A.; Vehling-Kaiser, U.; Al-Batran, S.-E.; Heintges, T.; Lerchenmüller, C.; Kahl, C.; Seipelt, G.; Kullmann, F.; Stauch, M.; Scheithauer, W.; Held, S.; Moehler, M.; Jung, A.; Kirchner, T. und Heinemann, V.
(2016):
Clinical relevance of subsequent treatment procedures on overall survival in FIRE-3/AIO KRK0306 (FOLFIRI plus cetuximab [arm A] or bevacizumab [arm B]) in patients with KRAS wild-type metastatic colorectal cancer.
In: Oncology Research and Treatment, Bd. 39: S. 11
Michl, M.; Stintzing, S.; Fischer von Weikersthal, L.; Decker, T.; Kiani, A.; Vehling-Kaiser, U.; Al-Batran, S.-E.; Heintges, T.; Lerchenmüller, C.; Kahl, C.; Seipelt, G.; Kullmann, F.; Stauch, M.; Scheithauer, W.; Hielscher, J.; Scholz, M.; Mueller, S.; Lerch, M. M.; Modest, D. P.; Kirchner, T.; Jung, A. und Heinemann, V.
(2016):
CEA response is associated with tumor response and survival in patients with KRAS exon 2 wild-type and extended RAS wild-type metastatic colorectal cancer receiving first-line FOLFIRI plus cetuximab or bevacizumab (FIRE-3 trial)(aEuro).
In: Annals of Oncology, Bd. 27, Nr. 8: S. 1565-1572
Stintzing, S.; Fischer von Weikersthal, L.; Decker, T.; Kiani, A.; Vehling-Kaiser, U.; Al-Batran, S.-E.; Heintges, T.; Lerchenmueller, C.; Kahl, C.; Seipelt, G.; Kullmann, F.; Stauch, M.; Hielscher, J.; Lerch, M.; Scheithauer, W.; Jagenburg, A.; Held, S.; Modest, D.; Jung, A.; Kirchner, T. und Heinemann, V.
(2016):
BRAF mutant and RAS mutant patients treated with FOLFIRI plus Bevacizumab or FOLFIRI plus Cetuximab. Role of ETS and molecular markers in FIRE-3 (AIO KRK-0306).
In: Annals of Oncology, Bd. 27: S. 112
2015
Michl, M.; Heinemann, V.; Jung, A.; Engel, Jutta; Kirchner, T. und Neumann, J.
(2015):
Expression of cancer stem cell markers in metastatic colorectal cancer correlates with liver metastasis, but not with metastasis to the central nervous system.
In: Pathology, Research and Practice, Bd. 211, Nr. 8: S. 601-609
Heinemann, V.; Stintzing, S.; Modest, D. P.; Giessen-Jung, C.; Michl, M. und Mansmann, Ulrich
(2015):
Early tumour shrinkage (ETS) and depth of response (DpR) in the treatment of patients with metastatic colorectal cancer (mCRC).
In: European Journal of Cancer, Bd. 51, Nr. 14: S. 1927-1936
Michl, M.; Thurmaier, J.; Schubert-Fritschle, Gabriele; Wiedemann, Max; Laubender, Rüdiger P.; Nussler, N. C.; Ruppert, R.; Kleeff, J.; Schepp, W.; Reuter, C.; Lohe, F.; Karthaus, M.; Neumann, J.; Kirchner, T.; Engel, Jutta und Heinemann, V.
(2015):
Brain Metastasis in Colorectal Cancer Patients: Survival and Analysis of Prognostic Factors.
In: Clinical Colorectal Cancer, Bd. 14, Nr. 4: S. 281-290
Stahler, A.; Heinemann, V.; Giessen-Jung, C.; Crispin, Alexander; Schalhorn, A.; Stintzing, S.; Fischer von Weikersthal, L.; Vehling-Kaiser, U.; Stauch, M.; Quietzsch, D.; Held, S.; Einem, J. C. von; Holch, J.; Neumann, J.; Kirchner, T.; Jung, A. und Modest, D. P.
(2015):
Influence of mRNA expression of epiregulin and amphiregulin on outcome of patients with metastatic colorectal cancer treated with 5-FU/LV plus irinotecan or irinotecan plus oxaliplatin as first-line treatment (FIRE 1-trial).
In: International Journal of Cancer, Bd. 138, Nr. 3: S. 739-746
2014
Michl, M.; Haug, A. R.; Jakobs, T. F.; Paprottka, P.; Hoffmann, R. T.; Bartenstein, P.; Boeck, S.; Haas, M.; Laubender, Rüdiger P. und Heinemann, V.
(2014):
Radioembolization with Yttrium-90 Microspheres (SIRT) in Pancreatic Cancer Patients with Liver Metastases: Efficacy, Safety and Prognostic Factors.
In: Oncology, Bd. 86, Nr. 1: S. 24-32
Michl, M.; Haug, A. R.; Jakobs, T. F.; Paprottka, Philipp M.; Hoffmann, R.-T.; Bartenstein, P.; Boeck, S.; Haas, M.; Laubender, R. P. und Heinemann, V.
(2014):
Radioembolization with Yttrium-90 microspheres (SIRT) in pancreatic cancer patients with liver metastases: Efficacy, safety and prognostic factors.
In: Oncology, Bd. 86, Nr. 1: S. 24-32
[PDF, 265kB]
Boeck, S.; Ormanns, S.; Haas, M.; Bachmann, S.; Laubender, Rüdiger P.; Siveke, J. T.; Jung, A.; Kirchner, T. und Heinemann, V.
(2014):
Translational research in pancreatic cancer: KRAS and beyond.
In: Pancreas, Bd. 43, Nr. 1: S. 150-152
2013
Giessen, C.; Graeven, U.; Laubender, Rüdiger P.; Modest, D. P.; Schulz, C.; Porschen, R.; Schmiegel, W.; Reinacher-Schick, A.; Hegewisch-Becker, S.; Stintzing, S. und Heinemann, V.
(2013):
Prognostic factors for 60-day mortality in first-line treatment of metastatic colorectal cancer (mCRC): individual patient analysis of four randomised, controlled trials by the AIO colorectal cancer study group.
In: Annals of Oncology, Bd. 24, Nr. 12: S. 3051-3055
Heinemann, V.; Ebert, M. P.; Laubender, Rüdiger P.; Bevan, P.; Mala, C. und Boeck, S.
(2013):
Phase II randomised proof-of-concept study of the urokinase inhibitor upamostat (WX-671) in combination with gemcitabine compared with gemcitabine alone in patients with non-resectable, locally advanced pancreatic cancer.
In: British Journal of Cancer BJC, Bd. 108, Nr. 4: S. 766-770
Modest, D. P.; Camaj, P.; Heinemann, V.; Schwarz, B.; Jung, A.; Laubender, Rüdiger P.; Gamba, S.; Haertl, C.; Stintzing, S.; Primo, S. und Bruns, C. J.
(2013):
KRAS allel-specific activity of sunitinib in an isogenic disease model of colorectal cancer.
In: Journal of Cancer Research and Clinical Oncology, Bd. 139, Nr. 6: S. 953-961
Modest, D. P.; Laubender, Rüdiger P.; Stintzing, S.; Giessen, C.; Schulz, C.; Haas, M.; Mansmann, Ulrich und Heinemann, V.
(2013):
Early tumor shrinkage in patients with metastatic colorectal cancer receiving first-line treatment with cetuximab combined with either CAPIRI or CAPOX: An analysis of the German AIO KRK 0104 trial.
In: Acta Oncologica, Bd. 52, Nr. 5: S. 956-962
Meimarakis, G.; Angele, Martin Kurt; Conrad, C.; Schauer, R.; Weidenhagen, R.; Crispin, Alexander; Giessen, C.; Preissler, G.; Wiedemann, Max; Jauch, K. W.; Heinemann, V.; Stintzing, S.; Hatz, R. A. und Winter, H.
(2013):
Combined resection of colorectal hepatic-pulmonary metastases shows improved outcome over chemotherapy alone.
In: Langenbeck's Archives of Surgery, Bd. 398, Nr. 2: S. 265-276
Haas, M.; Heinemann, V.; Kullmann, F.; Laubender, Rüdiger P.; Klose, C.; Bruns, C. J.; Holdenrieder, S.; Modest, D. P.; Schulz, C. und Boeck, S.
(2013):
Prognostic value of CA 19-9, CEA, CRP, LDH and bilirubin levels in locally advanced and metastatic pancreatic cancer: results from a multicenter, pooled analysis of patients receiving palliative chemotherapy.
In: Journal of Cancer Research and Clinical Oncology, Bd. 139, Nr. 4: S. 681-689
Zeiss, K.; Parhofer, K. G.; Heinemann, V.; Haas, M.; Laubender, Rüdiger P.; Holdenrieder, S.; Schulz, C. und Boeck, S.
(2013):
Glucose and lipid metabolism in patients with advanced pancreatic cancer receiving palliative chemotherapy.
In: Anticancer Research, Bd. 33, Nr. 1: S. 287-292
Boeck, S.; Jung, A.; Laubender, Rüdiger P.; Neumann, J.; Egg, R.; Goritschan, C.; Ormanns, S.; Haas, M.; Modest, D. P.; Kirchner, T. und Heinemann, V.
(2013):
KRAS mutation status is not predictive for objective response to anti-EGFR treatment with erlotinib in patients with advanced pancreatic cancer.
In: Journal of Gastroenterology, Bd. 48, Nr. 4: S. 544-548
Boeck, S.; Jung, A.; Laubender, Rüdiger P.; Neumann, J.; Egg, R.; Goritschan, C.; Vehling-Kaiser, U.; Winkelmann, C.; Fischer von Weikersthal, L.; Clemens, M. R.; Gauler, T. C.; Marten, A.; Klein, S.; Kojouharoff, G.; Barner, M.; Geissler, M.; Greten, T. F.; Mansmann, Ulrich; Kirchner, T. und Heinemann, V.
(2013):
EGFR pathway biomarkers in erlotinib-treated patients with advanced pancreatic cancer: translational results from the randomised, crossover phase 3 trial AIO-PK0104.
In: British Journal of Cancer BJC, Bd. 108, Nr. 2: S. 469-476
Giessen, C.; Laubender, Rüdiger P.; Fischer von Weikersthal, L.; Schalhorn, A.; Modest, D. P.; Stintzing, S.; Haas, M.; Mansmann, Ulrich und Heinemann, V.
(2013):
Early tumor shrinkage in metastatic colorectal cancer: Retrospective analysis from an irinotecan-based randomized first-line trial.
In: Cancer Science, Bd. 104, Nr. 6: S. 718-724
Giessen, C.; Fischer von Weikersthal, L.; Laubender, Rüdiger P.; Stintzing, S.; Modest, D. P.; Schalhorn, A.; Schulz, C. und Heinemann, V.
(2013):
Evaluation of prognostic factors in liver-limited metastatic colorectal cancer: a preplanned analysis of the FIRE-1 trial.
In: British Journal of Cancer BJC, Bd. 109, Nr. 6: S. 1428-1436
Giessen, C.; Laubender, Rüdiger P.; Ankerst, Donna Pauler; Stintzing, S.; Modest, D. P.; Mansmann, Ulrich und Heinemann, V.
(2013):
Progression-Free Survival as a Surrogate Endpoint for Median Overall Survival in mCRC: Literature-Based Analysis from 50 Randomized First-Line Trials.
In: Clinical Cancer Research, Bd. 19, Nr. 1: S. 225-235
2012
Modest, D. P.; Jung, A.; Moosmann, N.; Laubender, Rüdiger P.; Giessen, C.; Schulz, C.; Haas, M.; Neumann, J.; Boeck, S.; Kirchner, T.; Heinemann, V. und Stintzing, S.
(2012):
The influence of KRAS- and BRAF-mutations on the efficacy of cetuximab-based 1st-line therapy of metastatic colorectal cancer: An analysis of the AIO KRK-0104 -trial.
In: International Journal of Cancer, Bd. 131, Nr. 4: S. 980-986
Modest, D. P.; Reinacher-Schick, A.; Stintzing, S.; Giessen, C.; Tannapfel, A.; Laubender, Rüdiger P.; Brodowicz, T.; Knittelfelder, R.; Vrbanec, D.; Schmiegel, W.; Heinemann, V. und Zielinski, C. C.
(2012):
Cetuximab-based or bevacizumab-based first-line treatment in patients with KRAS p.G13D-mutated metastatic colorectal cancer: a pooled analysis.
In: Anticancer Drugs, Bd. 23, Nr. 6: S. 666-673
Hofheinz, R. D.; Heinemann, V.; Fischer von Weikersthal, L.; Laubender, Rüdiger P.; Gencer, D.; Burkholder, I.; Hochhaus, A. und Stintzing, S.
(2012):
Capecitabine-associated hand-foot-skin reaction is an independent clinical predictor of improved survival in patients with colorectal cancer.
In: British Journal of Cancer BJC, Bd. 107, Nr. 10: S. 1678-1683
Haas, M.; Laubender, Rüdiger P.; Klose, C.; Schulz, C.; Mansmann, Ulrich; Boeck, S. und Heinemann, V.
(2012):
External Validation of 2 Prognostic Indices for Patients With Advanced Pancreatic Cancer Treated With First-line Therapy.
In: Pancreas, Bd. 41, Nr. 5: S. 738-744
2011
Giessen, C.; Stintzing, S.; Laubender, Rüdiger P.; Ankerst, Donna Pauler; Schulz, C.; Moosmann, N.; Modest, D. P.; Schalhorn, A.; Fischer von Weikersthal, L. und Heinemann, V.
(2011):
Analysis for Prognostic Factors of 60-day Mortality: Evaluation of an Irinotecan-Based Phase III Trial Performed in the First-Line Treatment of Metastatic Colorectal Cancer.
In: Clinical Colorectal Cancer, Bd. 10, Nr. 4: S. 317-324
Modest, D. P.; Stintzing, S.; Laubender, Rüdiger P.; Neumann, J.; Jung, A.; Giessen, C.; Haas, M.; Aubele, P.; Schulz, C.; Boeck, S.; Stemmler, H. J.; Kirchner, T. und Heinemann, V.
(2011):
Clinical characterization of patients with metastatic colorectal cancer depending on the KRAS status.
In: Anticancer Drugs, Bd. 22, Nr. 9: S. 913-918
2010
Boeck, S.; Haas, M.; Laubender, Rüdiger P.; Kullmann, F.; Klose, C.; Bruns, C. J.; Wilkowski, R.; Stieber, P.; Holdenrieder, S.; Buchner, Hannes; Mansmann, Ulrich und Heinemann, V.
(2010):
Application of a time-varying covariate model to the analysis of CA 19-9 as serum biomarker in patients with advanced pancreatic cancer.
In: Clinical Cancer Research, Bd. 16, Nr. 3: S. 986-994
Kreis, M. E.; Junginger, T.; Rödel, C.; Heinemann, V.; Konstantin, N.; Mansmann, Ulrich und Jauch, K. W.
(2010):
Das Optimult-Studienkonzept - Grundlage für selektiven Einsatz neoadjuvanter Radiochemotherapie auf MRT-Basis?
In: Zentralblatt für Chirurgie, Bd. 135, Nr. 4: S. 302-306
Haas, M.; Laubender, Rüdiger P.; Stieber, P.; Holdenrieder, S.; Bruns, C. J.; Wilkowski, R.; Mansmann, Ulrich; Heinemann, V. und Boeck, S.
(2010):
Prognostic relevance of CA 19-9, CEA, CRP, and LDH kinetics in patients treated with palliative second-line therapy for advanced pancreatic cancer.
In: Tumor Biology, Bd. 31, Nr. 4: S. 351-357